Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT01679990
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 180 participants
- Sponsor
- Pluristem Ltd.
- Registry
-
NCT01679990
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Germany, Israel, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01679990. Randomized; double masking; primary purpose treatment. Start 2012-11-05 (registry gives no type); primary completion 2018-03-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
- Condition
- Intermittent Claudication
- Condition
- Peripheral Artery Disease
- Intervention (Biological)
- PLX-PAD Low dose
- Intervention (Biological)
- PLX-PAD high doses
- Intervention (Biological)
- Double Placebo
- Intervention (Biological)
- high dose +Placebo
- Lead sponsor
- Pluristem Ltd.
Record details
- Record id
cardio:ct-nct01679990- Content hash
ae88f02286b6bee6df90a43f21fcf02ea9e9c2719bb815e04e79c00df56d910d